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Summary. People with genetic haemochromatosis (GH)
accumulate iron from excessive dietary absorption. In
populations of northern European origin, over 90% of
patients are homozygous for the C282Y mutation of the
HFE gene. While about 1 in 200 people in the general
population have this genotype the proportion who develop
clinical haemochromatosis is not known. The influence of
HFE genotype on iron status was investigated in 10 556
blood donors. The allele frequencies of the C282Y and H63D
mutations were 8·23% and 15·3% respectively. Hetero-
zygosity for C282Y occurred in 1 in 7·9 donors, for H63D in
1 in 4·2 donors, and 1 in 42 were compound heterozygotes.
Homozygosity for H63D occurred in 1 in 42 donors and 1 in
147 (72) were homozygous for C282Y. Mean values
increased for transferrin saturation (TS) and serum ferritin
(sFn), and decreased for unsaturated iron binding capacity
(UIBC) in the order: donors lacking the mutations, H63D
heterozygotes, C282Y heterozygotes, H63D homozygotes,
compound heterozygotes and C282Y homozygotes, but
serum ferritin (sFn) concentrations were no higher in
H63D heterozygotes and C282Y heterozygous women than
in donors lacking mutations. The percentage of donors
failing the screening test for anaemia or of those with
sFn , 15 mg/l did not differ among the genotype groups.
C282Y and H63D heterozygotes and donors homozygous for
H63D were at no greater risk of iron accumulation than
donors lacking mutations, of whom 1 in 1200 had both a
raised TS and sFn. The risk was higher for compound
heterozygotes (1 in 80, P  0·003) and for C282Y
homozygotes (1 in 5, P , 0·0001). There was no correla-
tion between sFn and either age or donation frequency in
C282Y homozygotes. None of the 63 C282Y homozygous
donors interviewed showed physical signs of overload or
were aware of relatives with haemochromatosis. The Welsh
Blood Service collects blood from about 140 000 people
each year including an estimated 950 who are homozygous
for HFE C282Y. They are probably healthy and unaware of
any family history of iron overload.
Keywords: blood donation, HFE mutations, iron deficiency,
iron overload, population screening.
Genetic haemochromatosis (GH) is an autosomal recessive
disorder in which those affected accumulate iron as a result
of increased absorption from food (Bothwell & MacPhail,
1998). GH, defined in terms of iron accumulation, is
common in countries in which the population is largely of
northern European origin (Worwood, 1994a). If patients
are diagnosed in the precirrhotic stage and treated by
phlebotomy to remove the excess iron, life expectancy is
normal (Niederau et al, 1996). However, once cirrhosis has
developed patients have a shortened life expectancy and a
high risk of liver cancers, even when iron depletion has been
achieved.
In 1996, the HFE gene was located on the short arm of
chromosome 6 about 5 Mb telomeric to the human
leucocyte antigen (HLA) class I region (Feder et al, 1996).
It codes for a HLA class I-like protein and over 90% of
chromosomes from patients with GH carry a single
mutation, C282Y, on this gene (Feder et al, 1996). There
is convincing functional evidence for the involvement of the
HFE protein in iron transport across cell membranes, as the
HFE protein forms a complex with the transferrin receptor
and decreases the affinity of the receptor for transferrin
(Feder et al, 1998; Lebron et al, 1998). HFE knockout mice
develop a similar form of iron overload to humans (Zhou
et al, 1998). The C282Y mutation abolishes a disulphide
bridge, which prevents binding to b2 microglobulin and cell-
surface expression (Feder et al, 1997). A second mutation,
H63D, is common in the general population, but may cause
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iron accumulation if present with the C282Y mutation
(Feder et al, 1996). In Europe, Australia and the USA, from
60% to 100% of patients with GH are homozygous for the
C282Y mutation of the HFE gene (Worwood, 1999). In the
general population, the C282Y mutation frequency varies
from 0·5% in Italy to over 9% in Ireland and parts of
Brittany. The mutation is not found in non-European
populations. The H63D mutation is more widespread and
in Europe the frequency is 12–15% (Merryweather-Clarke
et al, 2000). In the UK, over 90% of patients with GH are
homozygous for the C282Y mutation of the HFE gene and
another 4% are compound heterozygotes (The UK Haemo-
chromatosis Consortium & Worwood, 1997). Other forms of
non-HFE-related haemochromatosis include those patients
with clinical haemochromatosis who lack detectable muta-
tions in the HFE gene and any HLA haplotype association
(Pietrangelo et al, 1999; Roetto et al, 2001).
On first investigation, most homozygous relatives of a
haemochromatosis patient show evidence of iron accumu-
lation (a raised transferrin saturation; TS) and about 50% of
men and a lower proportion of women display at least one of
the clinical manifestations of haemochromatosis: hepato-
megaly, abdominal pain, skin pigmentation, weight loss,
fatigue, arthropathy, hypogonadism, impotence, liver dis-
ease and cirrhosis (Bradley et al, 1996).
There are now several reports about clinical penetrance
in subjects homozygous for C282Y detected by genetic
testing. Olynyk et al (1999) found similar figures for
penetrance in a population-based study of 3011 unrelated,
white adults in Busselton, Australia, where homozygotes for
haemochromatosis were detected by genetic testing. How-
ever, other population-based studies of both blood donors
(Adams et al, 2000) and non-blood donors (Beutler et al,
2000) have revealed a lower clinical penetrance for
homozygosity for C282Y.
Early population studies suggested an incidence of 1 in
5000 to 1 in 10 000 for clinical haemochromatosis
(Sheldon, 1935; Finch & Finch, 1955). In the island of
Jersey, where the C282Y allele frequency is 8·4% (Merry-
weather-Clarke et al, 1998), about 1 in 140 people would be
homozygous for C282Y yet the population prevalence for
clinical haemochromatosis was 1 in 4700. Haemochroma-
tosis or iron overload was mentioned in about 1 in 6000
death certificates in the USA from 1979 to 1992 (Yang et al,
1998). The frequency of heterozygosity and homozygosity
for C282Y was not significantly increased in patients with
type II diabetes (Braun et al, 1998; Frayling et al, 1998;
Florkowski et al, 1999) and liver disease (Bhavnani et al,
2000; Willis et al, 2000). It is therefore already apparent
that the majority of C282Y homozygotes are not being
detected clinically.
Motulsky (1979) suggested that the haemochromatosis
gene may have spread because of a selective advantage –
protection of heterozygotes against iron deficiency. About
25% of heterozygotes, identified by HLA typing of family
members of haemochromatosis patients, have either a raised
TS or a raised serum ferritin (sFn) (Powell et al, 1990;
Adams, 1994; Bulaj et al, 1996). Slightly but significantly
higher values for serum iron (sFe) and TS have been found
in heterozygotes for either C282Y (Burt et al, 1998; Datz
et al, 1998; Beutler et al, 2000) or H63D (Burt et al, 1998;
Beutler et al, 2000) compared with subjects lacking these
mutations. The differences in ferritin levels were smaller and
not significant. In compound heterozygotes, there are
greater differences (Beutler et al, 2000; Rossi et al, 2000).
In heterozygotes for C282Y (Datz et al, 1998; Beutler et al,
2000) and H63D (Beutler et al, 2000), Hb levels were
slightly higher than in subjects lacking mutations. Beutler
et al (2000) have noted a lower prevalence of anaemia
among women carrying either mutation, but the differences
are small and only significant if all subjects carrying
mutations were compared with those lacking mutations.
Such changes may indicate an increase in iron absorption
that might permit C282Y heterozygotes to donate blood
more frequently than donors without the mutation.
We have studied the effect of HFE mutations on iron
status by examining HFE genotypes and measures of iron
status in blood donors. Blood donors are relatively young
and fit and this largely removes the influence of disease on
measures of iron status. By studying large numbers, the
dietary influences on genotype are equalized. Blood donors
also have greater iron losses as a result of donation of blood.
However, this additional iron loss can be quantified along
with the number of times that a donor has not been
permitted to give blood because of possible anaemia.
SUBJECTS AND METHODS
Subjects. Blood samples were collected during a period of
7 months beginning in July 1998. People attending Welsh
Blood Service sessions in South Wales at which more than
100 donations were expected were invited to take part in the
study. A donor assistant offered an information sheet to
those attending and invited them to sign the consent form.
The assistant was available to answer questions about the
project but had no knowledge of the medical or donation
histories of the potential donors. Samples were available
from all potential donors who signed the consent form,
including those who failed the ‘copper sulphate’ screening
test for anaemia and were therefore deferred as blood
donors. After the session, samples corresponding to the
completed consent forms were identified and both blood and
serum were stored in microtitre plates (1 ml well volume) at
2208C. The protocol was approved by the Bro Taf Research
Ethics Committee. Donors were able to withdraw their
consent for testing at any time. Only donors homozygous for
the HFE C282Y mutation (or who had both abnormal TS
and sFn results) were informed of the genotype result. These
donors were contacted and offered an interview with one of
the authors in order to provide counselling, confirm the test
results, provide treatment if necessary and advice on family
testing. If results were not obtained from a blood sample, for
any reason, this was explained to the donor in a letter and
he or she was invited to attend a donor session to give
another sample. Results were made available to any other
donors requesting this information.
Genotyping. DNA was prepared using the Dynabead DNA
Direct System 1 (Dynal, UK) and samples were genotyped
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using the polymerase chain reaction–single-stranded poly-
morphism (PCR–SSP) method of Guttridge et al (1998). This
single-step method does not use the reverse primer for
C282Y recently implicated in possible mistyping (Jeffrey et al,
1999; Merryweather-Clarke et al, 1999) and also permits
detection of 63D and 282Y in cis-linkage. 63H and 282Y
did not occur on the same chromosome. For donors
homozygous for HFE C282Y, results were confirmed on a
second sample by heteroduplex analysis (Worwood et al,
1999). There were no discrepancies.
Iron and ferritin assays. Serum iron (sFe) concentrations
and unsaturated iron binding capacity (UIBC) were
determined by a microtitre plate version (Worwood, 2001)
of the method of Persijn et al (1971). The total volume
required was 160 ml. The total iron binding capacity (TIBC)
was calculated as the sum of sFe and UIBC and the
percentage TS as the sFe/TIBC  100. Serum ferritin (sFn)
concentrations were determined as described by Worwood
(1995). Data from the microtitre plate reader were
transferred to a PC for calculation of sFe and UIBC using
Minitab (v 11).
Serum samples were added directly to microtitre plates
from the storage trays using a multichannel pipette. Fifty-
five assays for sFe, UIBC and sFn were carried out over a
period of 3 months. Each batch of assays for sFe and UIBC
consisted of a plate containing standards and control
preparations in quadruplicate and three microtitre plates
containing serum samples (assayed singly). For ferritin
assays, the first plate included standards and two control
sera (in duplicate) followed by up to three plates containing
samples (assayed singly). Intrabatch variation was deter-
mined using a control serum from a patient with genetic
haemochromatosis undergoing therapeutic phlebotomy.
This provided an estimate of imprecision close to the
diagnostic thresholds for iron overload. The sFe concentra-
tion was 27·1 ^ 1·4 mmol/l (mean ^ SD, n  96), the
UIBC 20·9 ^ 1·0 mmol/l (n  96), the TIBC was
48·0 ^ 1·6 mmol/l and the TS 56·5 ^ 1·9%. The coeffi-
cient of variation (CV) for sFe was 5·2%, for UIBC 4·8%, for
TIBC 3·3% and for TS 3·4%. At a ferritin concentration of
130 mg/l, the intrabatch CV was 7·8% (n  96). Interbatch
variation was assessed using Biorad Lyphochek, assayed
clinical chemistry control 1, for sFe, UIBC and TS. For 55
assays the mean ^ SD for sFe was 36·5 ^ 2·0 mmol/l, UIBC
10·8 ^ 2·9 mmol/l and TS 77·3 ^ 5·1%. The respective
values for CV were 6·5%, 26·9% and 6·6%. For control 2,
sFe was 12·1 ^ 1·5 mmol/l, UIBC 21·6 ^ 3·0 mmol/l and
TS 36·0 ^ 4·3%. The respective values for CV were 12·4%,
13·9% and 11·9%. A pooled, local control and Biorad
Anaemia Control were assayed for sFn. Mean values were
176 ^ 17·6 and 9·4 ^ 1·7 mg/l (CV 10·0 and 18·1%).
Statistics. Statistical calculations including multiple,
linear regression analysis were made using Microsoft Excel
and Minitab v 11. sFe, UIBC, TIBC and TS were expressed as
mean ^ SD and differences between groups of subjects
evaluated using the two-sample t-test. As serum ferritin
concentrations were not normally distributed, results were
expressed as median and 95% range, and differences
between groups were evaluated using the Mann–Whitney
test. Differences were regarded as significant if P , 0·05.
For the genotype comparisons, differences were regarded as
significant if P , 0·01 (using the Bonferroni correction for
five comparisons). Differences in frequency of iron overload
for the various genotypes were assessed using Fisher’s exact
test.
RESULTS
HFE genotypes
Almost all donors approached agreed to take part in the
study. There were 10 556 samples available for genotyping
– 5470 from women and 5086 from men. The C282Y
mutation frequency was 8·23% and the H63D mutation
frequency 15·2%. Genotype frequencies for all donors are
given in Table I. The observed distribution of genotypes did
not differ from the expected distribution (Hardy–Weinberg
equilibrium). Frequencies were not significantly different for
men and women. When donors were divided into age-
groups (, 31, 31–50, . 50 years), there were no sig-
nificant differences in genotype frequencies for men or
women. When genotype frequencies were calculated
according to postcode (Newport, NP; Cardiff, CF; Swansea,
SA), there were no differences in frequency.
Age, blood donation, iron status and HFE genotype
For 10 379 of these donors an adequate serum sample was
available for analysis. The mean age of the 5005 men was
greater than for the 5374 women tested (37·8 ^ 11·5
years and 35·7 ^ 11·5 years, mean ^ SD, P , 0·0001).
There were no significant differences between the mean
ages for any genotype group and the mean for all donors.
Men had given a mean of 2·7 ^ 2·0 units of whole blood in
the 3 years prior to testing and women 2·1 ^ 1·8 units
(P , 0·0001). There were no significant differences in
donation frequency between the genotypes except for the
men homozygous for C282Y who had given a mean of
3·7 ^ 1·9 units in the previous 3 years (compared with all
men, P , 0·01). This is partly explained by the observation
that only one of these (3%) was a first-time donor compared
with 12% of all male donors. However, even after excluding
first-time donors, the difference remains significant (all men,
3·1 ^ 1·9; C282Y homozygotes 3·8 ^ 1·8 units/3 years;
P , 0·05). Serum iron, TS and sFn concentrations were
Table I. HFE genotypes in blood donors (n  10556).
Genotype* Number of donors % of donors
HHCC 6152 58·3
HDCC 2488 23·6
HHCY 1342 12·7
DDCC 249 2·4
HDCY 253 2·4
HHYY 72 0·68
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous
H63D, DDCC, etc.
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significantly higher in men than in women (Tables II and
III) and the UIBC was lower (P , 0·0001). For men there
was a positive correlation between TS and sFn (r  0·119,
P , 0·0001) and a negative correlation between UIBC and
sFn (r  0·60, P , 0·0001). For women the corresponding
values were 0·237 (P , 0·0001) and 0·258 (P , 0·0001).
Tables II and III also summarize measures of iron status
for donors of each genotype. There were significant
differences for sFe, UIBC, TIBC and TS between mean values
for donors lacking mutations and all other genotype groups.
sFn also differed except that the median value for H63D
heterozygotes was not significantly different from donors
lacking mutations and C282Y heterozygous women did not
have a higher, median sFn than women lacking mutations.
Serum ferritin concentrations increased with age and
decreased with donation frequency in all genotype groups
except C282Y homozygotes and female H63D homozygotes
(Tables IV and V). The decrease in sFn with donation
frequency is shown in Fig 1 for men lacking mutations.
The percentage of donors failing the copper sulphate
screening test for anaemia during the 3 years preceding
testing or with a sFn less than 15 mg/l at the time of testing
was calculated. Only donors who had given at least 2 units
of blood were included. Overall 16·3% of women failed the
screening test and 4·5% of men. At the time of testing, 8% of
women and 0·9% of men had a sFn less than 15 mg/l. There
were no significant differences in frequencies between
donors lacking HFE mutations and any other genotype
groups for both men and women.
First-time donors
First-time donors comprised 12% of all male donors and
16% of women. They were younger than the whole group.
For men, the mean age was 28·3 ^ 10·5 years, compared
with 37·8 ^ 11·5 years for all men (P , 0·0001). For
women, the mean age was 26·8 ^ 10·5 years years
compared with 35·7 ^ 11·5 (P , 0·0001). Among both
men and women sFe, UIBC, TIBC, TS and sFn did not differ
between C282Y heterozygotes, H63D heterozygotes and
donors lacking mutations (Tables VI and VII). In men, the
mean UIBC was significantly lower than in donors lacking
mutations for homozygotes for H63D and compound
heterozygotes. Mean TS was also significantly higher in
the latter group. In women, mean values for UIBC were
significantly lower in homozygotes for H63D and all values
were significantly different from donors lacking mutations
for compound heterozygotes and homozygotes for C282Y.
Variation with age for the measures of iron status was
Table II. Iron status and genotype in male blood donors (mean ^ SD).
Genotype*
Number of donors (%)
SFe
(mmol/l)
UIBC
(mmol/l)
TIBC
(mmol/l)
TS
(%)
sFn
(mg/l)†
All donors: 4952 (100) 16·7 ^ 6·4 39·2 ^ 11·2 55·8 ^ 10·6 30·0 ^ 12·1 81 (24–196)
HHCC: 2896 (58·5) 16·0 ^ 6·1 40·8 ^ 11·0 56·8 ^ 10·6 28·3 ^ 11·0 79 (23–193)
HDCC: 1167 (23·6) 17·4 ^ 6·5‡ 38·2 ^ 10·5‡ 55·6 ^ 10·4§ 31·8 ^ 11·7‡ 81 (23–197)
HHCY: 644 (13·0) 17·3 ^ 6·0‡ 35·8 ^ 10·0‡ 53·1 ^ 10·0¶ 33·1 ^ 11·5‡ 82 (29–201)¶
DDCC: 105 (2·1) 19·1 ^ 6·9‡ 34·4 ^ 10·5‡ 53·5 ^ 10·1§ 36·4 ^ 13·1‡ 99 (33–210)‡
HDCY: 111 (2·2) 20·2 ^ 6·9‡ 31·2 ^ 12·1‡ 51·4 ^ 11·6‡ 40·5 ^ 15·5‡ 107 (24–260)‡
HHYY: 29 (0·59) 27·5 ^ 9·9‡ 15·6 ^ 8·4‡ 43·1 ^ 8·3‡ 63·6 ^ 17·8‡ 154 (50–410)‡
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc.
†Median (95% range). Mann–Whitney test for significance.
Significance of difference from wild-type donors ‡P , 0·0001, §P , 0·001, ¶P , 0·01.
Table III. Iron status and genotype in female blood donors (mean ^ SD).
Genotype*
Number of donors (%)
SFe
(mmol/l)
UIBC
(mmol/l)
TIBC
(mmol/l)
TS
(%)
sFn
(mg/l)†
All donors: 5373 (100) 14·3 ^ 6·3 42·9 ^ 12·9 56·8 ^ 11·2 25·4 ^ 12·4 44 (9–130)
HHCC: 3100 (57·7) 13·8 ^ 6·1 44·2 ^ 12·1 58·1 ^ 11·4 24·6 ^ 10·9 44 (9–126)
HDCC: 1277 (23·8) 14·7 ^ 6·2§ 41·5 ^ 12·2‡ 56·2 ^ 10·9‡ 27·0 ^ 12·0‡ 43 (10–127)
HHCY: 682(12·7) 14·6 ^ 6·1¶ 40·7 ^ 12·5§ 55·1 ^ 11·5‡ 27·3 ^ 12·1‡ 44 (8–116)
DDCC: 135 (2·5) 15·6 ^ 7·1§ 38·4 ^ 11·8‡ 54·0 ^ 11·1‡ 29·5 ^ 13·8‡ 46·5 (11–140)
HDCY: 138 (2·6) 16·6 ^ 6·8‡ 34·2 ^ 10·5‡ 50·8 ^ 8·6‡ 33·2 ^ 14·0‡ 50 (10–180)¶
HHYY: 41 (0·76) 21·4 ^ 8·4§ 23·4 ^ 12·6‡ 44·3 ^ 10·4‡ 49·9 ^ 20·5‡ 65 (8–238)§
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc.
†Median (95% range). Mann–Whitney test for significance.
Significance of difference from wild-type donors ‡P , 0·0001, §P , 0·001, ¶P , 0·01.
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examined in first-time donors. For male, first-time donors
there was a small but significant increase in sFn with age
(r  0·379, P , 0·0001). There were no significant
changes with age for sFe, UIBC, TIBC and TS. The
correlation between sFn and age is shown for donors
lacking mutations in Fig 2. There were similar correlations
for C282Y heterozygotes and H63D heterozygotes. Neither
the intercept on the y-axis nor the slope of the regression
line differed between these three groups. Numbers were
small in the other genotype groups but there was a
significant increase in TS with age in compound hetero-
zygotes (r  0·642, P  0·018).
Among first-time, female donors, sFn increased with age
(r  0·255, P , 0·0001) and sFe decreased (r  0·112,
P  0·0009). There were also small decreases for UIBC
(r  0·115, P  0·0006) and TIBC (r  0·186,
P , 0·0001), but not for TS. Serum ferritin concentrations
increased with age for donors lacking mutations
(sFn  30·6 1 0·834 age, r  0·262, P , 0·001), and
in C282Y heterozygous and H63D heterozygous women.
There were no significant differences in intercept on the y-
axis or slope of the regression line. We did not find the
expected correlations between age and sFn for compound
heterozygotes, H63D homozygotes and C282Y homozy-
gotes, possibly because of the small numbers in these
groups.
HFE genotype and iron accumulation
In order to determine reference ranges for the various
measures of iron status in the absence of any influence from
blood donation and HFE mutations, mean values were
calculated for first-time donors lacking mutations. Although
iron and ferritin concentrations are expected to increase in
women after the menopause, only 19 of the 540 women were
over the age of 50 years and these donors were not excluded.
Upper limits (or in the case of the UIBC, lower limits) have been
determined for the various measures of iron status. For sFe,
UIBC and TS this value was 1·96SD from the mean. For sFn,
the 97·5 percentile is given. The limits were sFe . 28 mmol/
l, UIBC , 20 mmol/l, TS . 50% and sFn . 210 mg/l (men)
or 130 mg/l (women).
In Tables VIII and IX, the number of donors with sFe, TS
and sFn values above the reference range, or UIBC values
below the reference range, are shown. There were only 14
men (eight homozygous for C282Y) and 16 women (seven
homozygous for C282Y) with both high TS and sFn. The
age distribution among C282Y homozygous donors was the
same as that for all donors, but there was no correlation
between sFn and age or donation frequency in C282Y
homozygotes in contrast to other donors (Tables IV and V).
TS declined with age for the 10 female, first-time donors
(linear regression analysis: TS  80·5–0·943 age,
r  0·61, P  0·035).
Table IV. Multiple regression analysis, sFn with age and donation frequency in males.
Significance (P)
Genotype* Regression equation R Age (years) Number of donations in 3 years
HHCC Fn  85·4 1 0·662 age28·80D 0·371 , 0·0001 , 0·0001
HDCC Fn  87·4 1 0·673 age28·57D 0·351 , 0·0001 , 0·0001
HHCY Fn  90·5 1 0·682 age28·87D 0·371 , 0·0001 , 0·0001
DDCC Fn  109 1 0·543 age29·93D 0·313 , 0·0001 , 0·0001
HDCY Fn  83·5 1 1·80 age213·2D 0·470 , 0·0001 , 0·0001
HHYY Fn  116 1 3·82 age216·1D 0·110 0·153 0·297
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc; D, units of blood donated in the 3 years prior to testing.
Table V. Multiple regression analysis, sFn with age and donation frequency in women.
Significance (P)
Genotype* Regression equation R Age (years) Number of donations in 3 years
HHCC Fn  36·7 1 0·534 age22·95D 0·202 , 0·0001 , 0·0001
HDCC Fn  36·1 1 0·541 age22·74D 0·205 , 0·0001 , 0·0001
HHCY Fn  36·4 1 0·526 age22·70D 0·197 , 0·0001 , 0·0001
DDCC Fn  35·8 1 0·602 age21·18D 0·055 0·127 0·636
HDCY Fn  33·5 1 1·20 age27·62D 0·311 , 0·0001 , 0·002
HHYY Fn  38·3 1 1·93 age291D 0·176 0·093 0·226
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc; D, units of blood donated in the 3 years prior to testing.
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Males who were homozygous for C282Y had donated a
total of 15 ^ 13 units of blood (mean ^ SD). If it was
assumed that blood was donated regularly since the age of
18 years, they had given 0·8 ^ 0·5 units of blood/year.
Female donors homozygous for C282Y had given
6·4 ^ 7·5 units in total (0·4 ^ 0·5 units/year). Only 2 of
the 63 homozygous donors interviewed to date had possible,
early symptoms of iron overload. Both were female: one
with arthralgia and one with abdominal pain. None showed
physical signs of overload and none were aware of relatives
with haemochromatosis. There were three female donors
homozygous for C282Y with sFn , 15 mg/l. There was
only one donor with evidence of iron overload (TS . 50%
and sFn . 300/200 mg/l, men/women) who was not
homozygous for HFE C282Y (a woman homozygous for
H63D with TS 63% and sFn 442 mg/l). On repeat testing,
her iron status was normal.
DISCUSSION
About 1 in 7 donors carried the C282Y mutation and 1 in 4
the H63D mutation. These frequencies are among the
highest in Europe. While donors were not asked about
ethnic origin, the ethnic communities are known to be
under-represented. Within the area included in the survey,
about 3·0% belong to ethnic minorities and, of these, nearly
67% are Asian, Black or of Mediterranean origin (Hogg &
Modell, 1998; personal communication Dr A. May). The
C282Y mutation of the HFE gene is rarely found in non-
European populations and is uncommon in Southern Italy
and Greece. The H63D allele is found in Mediterranean
populations at a similar frequency to that among northern
Europeans, but elsewhere its frequency is lower although
variable (Merryweather-Clarke et al, 2000). As less than 3%
of blood donors were from the ethnic minorities, the
frequencies given above relate to the population of Northern
European origin.
Serum iron and ferritin concentrations are influenced by
age, sex, diet and disease, as well as by biological variation
within an individual and by methodological variation
(Worwood, 1994b). In the case of blood donors, the
frequency of blood donation also needs to be considered
(Milman & Sondergaard, 1984). Although there is diurnal
variation of serum iron concentration and blood was taken
between 10·00 and 18·00 h, samples were assayed in order
of collection and not according to sex or genotype, so
methodological and biological variation should be similar
for all genotypes.
There were no differences in age or donation frequency
between the genotype groups except among the male,
C282Y homozygotes who had given significantly more
blood than other donors. Generally sFe, TS and sFn
increased, and UIBC and TIBC decreased, in the order:
wild type, H63D heterozygotes, C282Y heterozygotes, H63D
homozygotes, compound heterozygotes and C282Y homo-
zygotes. Despite the statistical significance of these differ-
ences in iron status, they are small and only the mean UIBC
and TS in the male C282Y homozygotes lie outside the
normal range established for first-time blood donors.
For female donors, sFn did not differ between wild type,
C282Y or H63D heterozygotes and donors homozygous for
H63D. Although this may indicate that there is little change
in total body iron stores, it may also reflect a failure of sFn to
respond to an increase in iron concentration in hepatic
Fig 1. sFn concentration and blood donation frequency in 2944
male donors lacking HFE mutations. sFn  106–7·33D
(r  0·336, P , 0·001), in which D  number of units of blood
donated in the previous 3 years.
Table VI. Iron status in first-time, male blood donors (mean ^ SD).
Genotype*
Number of donors
SFe
(mmol/l)
UIBC
(mmol/l)
TIBC
(mmol/l)
TS
(%)
sFn
(mg/l)†
All donors:612 16·7 ^ 6·0 37·7 ^ 9·9 54·2 ^ 10·0 31·1 ^ 10·9 101 (35–220)
HHCC: 376 16·2 ^ 5·9 38·6 ^ 9·6 54·8 ^ 11·1 29·7 ^ 10·2 101 (36–212)
HDCC: 135 17·5 ^ 6·0 37·8 ^ 11·4 55·3 ^ 10·1 31·6 ^ 11·1 98 (35–216)
HHCY: 74 16·7 ^ 6·0 35·0 ^ 10·4 51·8 ^ 9·6 32·1 ^ 12·2 117 (47–217)
DDCC: 12 20·4 ^ 8·0 31·8 ^ 11·0§ 52·1 ^ 9·0 39·6 ^ 15·9 109 (41–177)
HDCY: 14 19·3 ^ 3·8 28·4 ^ 9·1‡ 47·6 ^ 7·9 41·6 ^ 12·8‡ 130 (63–230)
HHYY: 1 10·0 25·3 35·3 28·4 149
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc.
†Median (95% range). Mann–Whitney test for significance.
‡P , 0·001, §P , 0·01 compared with wild-type (HHCC) genotype.
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parenchymal cells in the early stages of iron accumulation,
when iron concentrations in reticuloendothelial cells are
not increased (Worwood, 1990). Edwards et al (2000)
summarized reports of liver iron concentration in subjects
heterozygous for GH. Despite increases in liver iron
concentrations to about the upper limit of normal, serum
ferritin levels remained within the normal range.
Storage iron levels are influenced more by the frequency
of donation rather than by the total number of units given
(Milman & Søndergaard, 1984) and, in both men and
women, sFn decreased with the number of units of blood
given in the 3 years prior to testing. Storage iron levels were
calculated by assuming that 1 mg of sFn is equivalent to
8 mg of storage iron in the body (Walters et al, 1973).
Median iron stores for all donors were 0·65 g for men and
0·35 g for women. Among men with only wild-type alleles,
giving 3 units of blood, equivalent to 720 mg of Fe, in the
previous 3 years caused a reduction in the level of storage
iron of about 200 mg compared with those who had not
donated during the period. This is a result of the increased
iron absorption that is stimulated by blood donation (Garry
et al, 1995). The effect of blood donation on sFn
concentration was similar in donors lacking HFE mutations
and heterozygous donors.
If heterozygosity for C282Y provides young women with
protection against iron deficiency anaemia then it was not
apparent in our study. Serum ferritin concentrations did not
vary between heterozygotes and wild-type subjects and the
proportion of donors with sFn concentrations , 15 mg/l did
not differ. The proportion of donors failing the copper
sulphate screening test for anaemia was not decreased by
heterozygosity for C282Y. Thus, there was little indication
that heterozygotes for C282Y will be able to give blood more
frequently than donors not carrying this mutation. How-
ever, this finding is not in agreement with Beutler et al
(2000), who noted a small but significant reduction in the
prevalence of anaemia among subjects carrying HFE
mutations compared with those lacking mutations.
If storage iron levels are not increased in C282Y
heterozygotes, any association between heterozygosity for
HFE C282Y and disease (Dorak et al, 1999; Maclean et al,
1999; Roest et al, 1999; Tuomainen et al, 1999) may be
related to the subtle changes in plasma iron and iron
binding capacity. These changes may also explain the strong
association between both heterozygosity and homozygosity
for H63D in Italian patients with sporadic porphyria
cutanea tarda (Sampietro et al, 1998) in which the
C282Y mutation is rare. They may also be related to the
increase in non-transferrin-bound iron recently reported in
subjects heterozygous for C282Y (de Valk et al, 2000).
Approximately 1 in 1200 (90% CI 1 in 690 to 1 in 4545)
donors lacking mutations and H63D heterozygotes had both
a raised TS and sFn (based on the thresholds established for
first-time donors lacking mutations). For C282Y hetero-
zygotes, 1 in 437 (90% CI 1 in 225 to 1 in 7692) had raised
levels. For donors homozygous for H63D, 1 in 200 (1 in 90
to . 1 in 10 000) had raised values for TS and sFn. These
donors are not at significant risk of iron overload compared
with donors lacking mutations (Fisher’s exact test,
P . 0·05). For compound heterozygotes, about 1 in 80
(90% CI 1 in 42 to 1429) had raised levels (P  0·003). For
C282Y homozygosity, about 1 in 4 male donors and 1 in 5
female donors had raised levels (1 in 4·6 90% CI 3·3 to 7·4
Table VII. Iron status in first time, female blood donors (mean ^ SD).
Genotype*
Number of donors
SFe
(mmol/l)
UIBC
(mmol/l)
TIBC
(mmol/l)
TS
(%)
sFn
(mg/l)†
All donors: 890 14·3 ^ 6·7 42·7 ^ 13·2 56·7 ^ 12·1 25·5 ^ 12·9 47 (9–136)
HHCC: 540 13·9 ^ 6·8 43·9 ^ 12·2 57·9 ^ 11·9 24·2 ^ 12·4 48 (9–136)
HDCC: 200 14·6 ^ 6·1 41·7 ^ 12·9 56·3 ^ 11·7 26·7 ^ 12·2 45 (9–123)
HHCY: 100 14·7 ^ 6·6 42·2 ^ 13·1 57·2 ^ 13·2 25·6 ^ 12·1 45 (7–123)
DDCC: 15 13·4 ^ 6·5 33·9 ^ 10·3¶ 52·1 ^ 9·0 28·7 ^ 13·6 53 (15–106)
HDCY: 26 17·2 ^ 5·6§ 31·6 ^ 9·6§ 47·6 ^ 7·9‡ 34·5 ^ 14·7§ 66¶ (22–199)
HHYY: 10 24·7 ^ 8·6§ 18·8 ^ 7·1§ 43·5 ^ 7·0‡ 56·4 ^ 15·1§ 101¶ (41–202)
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc.
†Median (95% range). Mann–Whitney test for significance.
‡P , 0·0001, §P , 0·001, ¶P , 0·01 compared with wild-type (HHCC) genotype.
Fig 2. sFn concentration and age in 376 male, first-time donors
lacking HFE mutations. sFn  52·7 1 1·90 (age). r  0·414,
P , 0·0001.
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P , 0·0001). It should also be noted that the threshold for
sFn was not the usual upper limit of normal taken for
diagnostic purposes and even fewer donors exceeded
300 mg/l (male) and 200 mg/l (female). Heterozygotes and
donors homozygous for H63D appear to be at little risk from
iron overload and, for compound heterozygotes, the risk is
an order of magnitude less than for C282Y homozygotes.
The UIBC has been proposed as a cheap and rapid
screening test for iron overload (Pintar et al, 1981; Adams
et al, 2000). In this survey the UIBC appears to have a
similar sensitivity and specificity to TS.
The mean age of the C282Y homozygous men was
38 years, reflecting that for all donors, only 8 years
younger than the mean age of 46 years at diagnosis for
251 patients (90% men) reported by (Niederau et al, 1996).
In a group of 200 patients (10% of whom were women),
responding to a questionnaire, the mean age of onset of
symptoms was only 41 years, even though a diagnosis of
GH was not usually made for several more years (McDonnell
et al, 1999). Bassett et al (1984) studied 34 relatives of
patients with GH who shared the same HLA haplotypes. All
were under 35 years of age and were classified by HLA
typing as homozygous for haemochromatosis. For men and
women the median TS was 87% and 67%, respectively, and
was 450 mg/l and 320 mg/l for sFn. A median of 7 g of iron
was removed by phlebotomy. Initial sFn correlated with iron
stores determined by phlebotomy (r  0·92) with the same
relationship between storage iron (determined by quantita-
tive phlebotomy) and sFn as that found in normal subjects
by Walters et al (1973). At the time of diagnosis, the patients
studied by Niederau et al (1996) had accumulated
21·2 ^ 1·1 g (SEM) of iron. If storage iron is estimated by
assuming that 1 mg of serum ferritin is equivalent to 8 mg
of storage iron (Walters et al, 1973), the median level of
storage iron in our study was 1·23 g for male blood donors
homozygous for C282Y and 0·52 g for female donors.
Median iron stores, calculated in the same way for all
donors, were 0·65 and 0·35 g respectively. There was thus
an order of magnitude difference in the level of iron stores
between blood donors homozygous for C282Y and patients
presenting with clinical symptoms of GH or homozygotes
found by screening the families of relatives. This is unlikely
to be solely as a result of the age difference.
Are the low iron stores a result of blood donation? While
regular blood donation reduces the level of storage iron,
there is partial compensation because of the increase in iron
absorption (Garry et al, 1995). Among men lacking HFE
mutations, donating 3 units of blood in 3 years caused a
mean reduction of 200 mg in iron stores, although
donation losses were about 700 mg. However, among
those homozygous for C282Y, there was no relationship
between donation frequency and sFn. An enhanced rate of
iron absorption in C282Y homozygotes may ensure that
iron losses as a result of donation are more fully
Table VIII. Number of male blood donors (%) with abnormal sFe and sFn levels.
Genotype*
Number
of donors**
sFe
(. 28 mmol/l)
UIBC
(, 20 mmol/l)
TS
(. 50%)
sFn
(. 210 mg/l) TS 1 sFn
HHCC 2896 119 (4·1) 43 (1·5) 103 (3·6) 38 (1·3) 2
HDCC 1152 72 (6·3) 34 (3·0) 70 (6·1) 15 (1·3) 1
HHCY 639 28 (4·4) 29 (4·5) 44 (6·9) 13 (2·0) 1
DDCC 104 8 (7·7) 9 (8·7) 12 (11·5) 3 (2·9) 0
HDCY 108 13 (12) 15 (14) 24 (22) 5 (4·5) 2
HHYY 29 9 (31) 22 (76) 25 (86) 10 (34) 8
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC, etc.
**Numbers differ slightly from Table II as donors were only included if all assay values were available.
Table IX. Number of female blood donors (%) with abnormal sFe and sFn levels.
Genotype*
Number
of donors**
sFe
(. 28 mmol/l)
UIBC
(, 20 mmol/l)
TS
(. 50%)
sFn
(. 130 mg/l) TS 1 sFn
HHCC 3057 68 (2·2) 35 (1·1) 68 (2·2) 43 (1·4) 3
HDCC 1262 37 (2·9) 32 (2·5) 54 (4·3) 19 (1·5) 2
HHCY 673 21 (3·1) 18 (2·7) 31 (4·6) 11 (1·6) 2
DDCC 134 5 (3·7) 6 (44) 11 (8·2) 4 (3·0) 1
HDCY 137 5 (3·6) 4 (2·9) 16 (11·7) 7 (5·1) 1
HHYY 40 8 (20) 20 (50) 18 (45) 9 (22) 7
*Wild type, HHCC; homozygous C282Y, HHYY; homozygous H63D, DDCC; etc.
**Numbers differ slightly from Table III as donors were only included if all assays were available.
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compensated (Lynch et al, 1989), thus explaining this lack
of relationship. An intriguing finding of ours is that male
donors homozygous for C282Y had donated significantly
more blood in the 3 years before testing than all donors
(3·7 units and 2·8 units). While this observation is of
interest, particularly because there may be an underlying
biological explanation, it should be noted that Barton et al
(1999) found that voluntary blood donation before diag-
nosis did not decrease the severity of iron overload.
Subjects homozygous for haemochromatosis might be
excluded as blood donors either because they do not feel well
or because they are receiving medical treatment. There is no
evidence to support exclusion of C282Y homozygotes. Based
on overall allele frequencies for men and women, we
expected to find 34 men and 42 women homozygous for
C282Y. There were 30 men and 42 women discovered by
genetic testing. Furthermore, the age distribution was the
same as that for all donors.
The C282Y genotype is present in 90% of patients with
haemochromatosis and is strongly associated with iron
accumulation in blood donors. Among first-degree relatives
of patients with clinical haemochromatosis, approximately
50% of subjects homozygous for HFE C282Y eventually
develop clinical complications of haemochromatosis (Brad-
ley et al, 1996). A similar penetrance was reported by
Olynyk et al (1999) among randomly selected subjects
discovered by genetic testing of the adult population of
Busselton, Australia. In other surveys, however, in which
subjects have been identified as homozygous for C282Y by
genetic testing, the penetrance has been lower (Adams et al,
2000; Beutler et al, 2000). Within the region served by the
Welsh Blood Service, about 140 000 people give blood each
year, of whom about 950 will be homozygous for C282Y.
Our data suggest that the great majority of these are
probably healthy subjects unaware of any family history of
iron overload. Locally, the clinical burden appears to be low.
Cardiff and the Vale of Glamorgan has a population of
434 000 and is part of the region covered by our survey.
The data from the current survey reveals that 1 in 150
people are homozygous for C282Y. If all men over 50 years
of age have clinical manifestations of iron overload, there
should be 480 men with GH. We used the ICD10
classification (haemochromatosis E83·1) to identify patients
from hospital records and validated the list of patients from
local knowledge and laboratory records. There were 31
patients (23 men) resident in the area and being treated in
the two district general hospitals for the years 1998–2000
(unpublished observations).
Prior to the discovery of the HFE gene, Edwards et al
(1988) surveyed 11 065 blood donors from Utah, USA. The
Utah donors were of similar mean age to the donors from
South Wales and they had similar mean values for non-
fasting TS (6·2% of Utah donors with TS . 50% compared
with 4·2% for South Wales). Within this Utah population of
donors, 18 men and eight women were classified as
homozygous for GH on the basis of a fasting TS (. 62%),
liver biopsy and family studies. As women were clearly
under-represented, the male data were used to calculate the
frequency of the GH genotype to be 0·0045 (1 in 222).
Unfortunately, data for the frequency of HFE mutations are
not yet available for the Utah population. In South Wales,
the frequency of homozygosity for HFE C282Y was 0·0068.
At the time of testing, 25/29 men and 18/41 women had a
TS . 50%. This confirms that most men homozygous for
C282Y would have been identified in the Utah study and
that less than 50% of the women would have been detected.
Measuring TS would fail to detect 20% of young men and
over 50% of women. In female, first-time donors homo-
zygous for C282Y we found that TS decreased with age, and
in people presenting at a health appraisal clinic, average age
58 years, Beutler et al (2000) found that only a minority of
those homozygous for C282Y had a raised TS. This suggests
that measuring TS may be less effective for detecting GH in
older people than in people aged 30–50 years, but numbers
in both studies were small.
While an alternative detection strategy for haemochro-
matosis is population screening by genetic testing, it is
apparent from our data and that of others that this will
identify large numbers of healthy people who are at risk
from iron accumulation, yet who may never suffer from the
consequences of iron overload. All those detected in this way
will need to be counselled and offered a family investigation.
Those not requiring immediate treatment require regular
testing to detect the onset of iron overload. There is an
urgent need to identify the cofactors that convert a relatively
benign process of iron accumulation into iron overload,
tissue damage and disease in a proportion of those
homozygous for HFE C282Y. Until these additional risk
factors are identified, it is likely that the costs to the
individual and community will outweigh the benefits.
Population screening for haemochromatosis has been
strongly advocated, as the condition is common and
preventable by regular blood donation (Allen & Williamson,
2000). However, our study lends support to those advocat-
ing a more cautious approach (Haddow & Bradley, 1999).
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